Emerging data suggest this peptide, a dual agonist targeting both incretin and another hormone, could represent a notable advancement for weight management . Initial clinical trials have shown considerable decreases in abdominal tissue, possibly exceeding current body composition treatments. Despite this, more evaluation is necessary to thoroughly